Literature DB >> 17431567

[Treatment of laryngeal movement disorders with botulinum toxins: part 1: History and mode of action].

C Schwemmle1, M Ptok.   

Abstract

Laryngeal dystonia (spasmodic dysphonia) is a movement disorder characterised by involuntary contractions of the laryngeal muscles involved in vocalisation. The introduction of botulinum toxin (BTX) in the treatment of laryngeal dystonia had a major clinical impact due to the striking improvement of symptoms. Most patients with severe types of spasmodic dysphonia are treated with injections of botulinum toxin type A. For patients with a resistance against type A toxin there is a new hypercleaned type A toxin or type B available. Research on type F toxin is also underway. In this article, the history of botulinum toxin, its therapeutic activity and possibilities for its use are described.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17431567     DOI: 10.1007/s00106-007-1553-5

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  21 in total

1.  Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.

Authors:  H Göschel; K Wohlfarth; J Frevert; R Dengler; H Bigalke
Journal:  Exp Neurol       Date:  1997-09       Impact factor: 5.330

2.  Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study.

Authors:  A Garcia; J E Fulton
Journal:  Dermatol Surg       Date:  1996-01       Impact factor: 3.398

3.  Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.

Authors:  A B Scott
Journal:  Ophthalmology       Date:  1980-10       Impact factor: 12.079

4.  Supraglottal injection of botulinum toxin type A in adductor type spasmodic dysphonia with both intrinsic and extrinsic hyperfunction.

Authors:  R Schönweiler; K Wohlfarth; R Dengler; M Ptok
Journal:  Laryngoscope       Date:  1998-01       Impact factor: 3.325

5.  Technique for injection of botulinum toxin through the flexible nasolaryngoscope.

Authors:  K Rhew; D A Fiedler; C L Ludlow
Journal:  Otolaryngol Head Neck Surg       Date:  1994-12       Impact factor: 3.497

6.  Local botulinum toxin in the treatment of spastic drop foot.

Authors:  R Dengler; U Neyer; K Wohlfarth; U Bettig; H H Janzik
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

7.  [The dosage of botulinum toxin type B in adductor type spasmodic dysphonia].

Authors:  R Schönweiler; P Zwirner
Journal:  HNO       Date:  2005-02       Impact factor: 1.284

Review 8.  [Botulinum toxin in otorhinolaryngology].

Authors:  S Rohrbach; R Laskawi
Journal:  HNO       Date:  2004-07       Impact factor: 1.284

9.  [Do psychological factors change in patients with spasmodic dysphonia after injections with botulinum-toxin?].

Authors:  C Kiese-Himmel; M Reeh; H Liebeck; P Zwirner
Journal:  Laryngorhinootologie       Date:  2002-10       Impact factor: 1.057

10.  Laryngeal dystonia: a series with botulinum toxin therapy.

Authors:  A Blitzer; M F Brin
Journal:  Ann Otol Rhinol Laryngol       Date:  1991-02       Impact factor: 1.547

View more
  1 in total

1.  Intratympanic application of botulinum toxin: experiments in guinea pigs for excluding ototoxic effects.

Authors:  Thorsten Zehlicke; Christoph Punke; Dirk Dressler; Hans Wilhelm Pau
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-09-01       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.